BR0314584A - Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors - Google Patents

Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors

Info

Publication number
BR0314584A
BR0314584A BR0314584-0A BR0314584A BR0314584A BR 0314584 A BR0314584 A BR 0314584A BR 0314584 A BR0314584 A BR 0314584A BR 0314584 A BR0314584 A BR 0314584A
Authority
BR
Brazil
Prior art keywords
groups
group
pharmaceutically acceptable
compound
compounds
Prior art date
Application number
BR0314584-0A
Other languages
Portuguese (pt)
Inventor
Yasuhiro Katsu
Kon-I Kana
Mikio Morita
Hirohide Noguchi
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32030864&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR0314584A publication Critical patent/BR0314584A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"COMPOSTOS PIPERIDINIL-IMIDAZOPIRIDINA NSUBSTITUìDA COMO MODULADORES DE RECEPTORES 5-HT~ 4~". A presente invenção refere-se a um composto de fórmula (I): onde R^ 1^ representa um átomo de hidrogênio ou um átomo de halogêneo; R^ 2^ representa um átomo de hidrogênio, etc; R^ 3^ representa um grupo alquila com desde 1 até 10 átomos de carbono; onde o referido grupo alquila em R^ 3 ^ é substituído por pelo menos um substituinte selecionado de um grupo consistindo em substituintes (x, os referidos substituintes a são selecionado de um grupo consistindo em grupos arila, grupos hidróxi, grupos oxo, etc; os referidos grupos arila com 6 a 10 átomos de arbono, os referidos grupos heterocíclicos e porções hetecíclicas nos grupos heterociclicarbonilas são grupos cíclicos e 5- a 10-membros contendo desde 1 a 4 heteroátomos selecionados de um grupo consistindo em átomos de nitrogênio, etc.; ou uma amida desse composto famaceuticamente aceitável, ou um éster desse composto famaceuticamente aceitável, e seus sais desse composto famaceuticamente aceitáveis. Estes compostos tem atividade e ligação ao receptor 5-HT~ 4~, e deste modo são úteis no tratamento de doença de refluxo gastroesofágica, dispepsia não ulcerosa, dispepsia funcional, síndrome do intestino irritável ou de doenças semelhantes em mamíferos, especialmente no homenm. Esta invenção também proporciona uma composição farmacêutica compreendendo o composto acima."NSUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT ~ 4 ~ RECEIVER MODULATORS". The present invention relates to a compound of formula (I): wherein R4 represents a hydrogen atom or a halogen atom; R 2 represents a hydrogen atom, etc .; R3 represents an alkyl group having from 1 to 10 carbon atoms; wherein said C1-4 alkyl group is substituted by at least one substituent selected from a group consisting of substituents (x, said substituents a are selected from a group consisting of aryl groups, hydroxy groups, oxo groups, etc; said aryl groups having 6 to 10 carbon atoms, said heterocyclic groups and heterocyclic moieties on heterocyclecarbonyl groups are cyclic 5- to 10-membered groups containing from 1 to 4 heteroatoms selected from a group consisting of nitrogen atoms, etc .; or an amide of such a pharmaceutically acceptable compound, or an ester of such a pharmaceutically acceptable compound, and pharmaceutically acceptable salts thereof, These compounds have 5-HT 4 receptor activity and binding, and are thus useful in treating reflux disease. gastroesophageal, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or similar mammalian diseases, This invention also provides a pharmaceutical composition comprising the above compound.

BR0314584-0A 2002-09-20 2003-09-08 Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors BR0314584A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41242602P 2002-09-20 2002-09-20
PCT/IB2003/003945 WO2004026868A1 (en) 2002-09-20 2003-09-08 N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators

Publications (1)

Publication Number Publication Date
BR0314584A true BR0314584A (en) 2005-08-09

Family

ID=32030864

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314584-0A BR0314584A (en) 2002-09-20 2003-09-08 Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors

Country Status (13)

Country Link
US (1) US6951867B2 (en)
EP (1) EP1543004A1 (en)
JP (1) JP2006502180A (en)
AR (1) AR041303A1 (en)
AU (1) AU2003259482A1 (en)
BR (1) BR0314584A (en)
CA (1) CA2499494A1 (en)
GT (1) GT200300208A (en)
MX (1) MXPA05003065A (en)
PA (1) PA8582901A1 (en)
TW (1) TW200406412A (en)
UY (1) UY27992A1 (en)
WO (1) WO2004026868A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0409592A (en) * 2003-04-21 2006-05-02 Pfizer imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
EP1689742B1 (en) * 2003-11-24 2010-03-17 Pfizer, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1758891A2 (en) * 2004-06-15 2007-03-07 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
DE602005016446D1 (en) 2004-11-05 2009-10-15 Theravance Inc 5-HT4 receptor agonist compounds
ATE431824T1 (en) 2004-11-05 2009-06-15 Theravance Inc QUINOLINONE-CARBOXAMIDE COMPOUNDS
ES2347265T3 (en) 2004-12-22 2010-10-27 Theravance, Inc. INDAZOL-CARBOXAMIDA COMPOUNDS.
KR20070107807A (en) 2005-03-02 2007-11-07 세라밴스 인코포레이티드 Quinolinone compounds as 5-ht4 receptor agonists
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009023253A2 (en) * 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (en) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010091411A1 (en) * 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
AU2010316106B2 (en) 2009-11-06 2015-10-22 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (en) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * Methods for treating fibromyalgia syndrome.
WO2011099305A1 (en) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CN107001379B (en) 2014-11-06 2022-11-01 Bial研发投资股份有限公司 Substituted pyrazolo [1,5-a ] pyrimidines and their use in the treatment of medical disorders
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
BR112018070586A8 (en) 2016-04-06 2023-04-11 Lysosomal Therapeutics Inc PYRAZOL[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US10787454B2 (en) 2016-04-06 2020-09-29 BIAL—BioTech Investments, Inc. Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452481A4 (en) 2016-05-05 2020-02-26 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b
US11345698B2 (en) * 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
GB2589573A (en) 2019-12-02 2021-06-09 Caterpillar Inc Bucket actuator assembly with resilient bump stop

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JP2643274B2 (en) 1988-04-08 1997-08-20 三菱化学株式会社 Imidazo [1,2-a] pyridine derivative
FR2646894B3 (en) * 1989-05-11 1991-07-12 Sleever Int PROCESS FOR CONTROLLING THE TEMPERATURE IN AN OVEN-TUNNEL OPEN AT ITS TWO ENDS, AND DEVICE FOR IMPLEMENTING THE PROCESS
US5219850A (en) 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5196547A (en) 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
AU3192295A (en) 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
AU762726B2 (en) 1998-03-31 2003-07-03 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
JP4032566B2 (en) 1999-06-21 2008-01-16 東レ株式会社 Light emitting element
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
EP1440071B1 (en) * 2001-10-22 2005-10-26 Pfizer Inc. Imidazopyridine compounds as 5-ht 4? receptor modulators

Also Published As

Publication number Publication date
US6951867B2 (en) 2005-10-04
AR041303A1 (en) 2005-05-11
CA2499494A1 (en) 2004-04-01
PA8582901A1 (en) 2004-05-26
GT200300208A (en) 2004-05-20
AU2003259482A1 (en) 2004-04-08
US20040127514A1 (en) 2004-07-01
WO2004026868A1 (en) 2004-04-01
UY27992A1 (en) 2004-04-30
MXPA05003065A (en) 2005-05-27
TW200406412A (en) 2004-05-01
JP2006502180A (en) 2006-01-19
EP1543004A1 (en) 2005-06-22

Similar Documents

Publication Publication Date Title
BR0314584A (en) Unsubstituted piperidinyl imidazopyridine compounds as modulators and 5-ht4 receptors
BR0314284A (en) Imidazopyridine Compounds as 5-ht4 Receptor Agonists
DE602005005167D1 (en) 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXYLIC ACID AMID DERIVATIVES WITH AGONISTIC ACTIVITY AT THE 5-HT4 RECEPTOR
BR0300018A (en) Oxo or oxypyridine compounds as 5-ht4 receptor modulators
BR0110240A (en) Compound, process for preparing a compound, process for producing an antibacterial effect on a warm-blooded animal, use of a compound, and pharmaceutical composition
AU572405B2 (en) Heterocyclic-substituted indole
BR0010391A (en) Compound, pharmaceutical composition, method of preparing a compound, and, use of a compound
BRPI0707491B8 (en) compounds useful as mineralocorticoid receptor modulating agents, said agents comprising the same and pharmaceutical compositions
EA199800394A1 (en) Pyrazolopyrimidines as CRF receptor antagonists
ATE164575T1 (en) SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS
BRPI0510598A (en) substituted aryl or heteroaryl amide compounds
ATE63914T1 (en) N6-DISUBSTITUTED PURINE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND MEDICATIONS CONTAINING THESE COMPOUNDS.
CZ290784B6 (en) Pyrido[3,2-e]pyrazinones, process of their preparation and use as well as pharmaceutical preparations based thereon
ATE461192T1 (en) QUINOLOONECARBONIC ACID COMPOUNDS WITH 5-HT4 RECEPTOR AGONISTIC EFFECT
BR0210733A (en) Useful piperidine derivatives useful as modulators of chemokine receptor activity
BRPI0409592A (en) imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
BR0016953A (en) Halogen substituted 4-phenyl-1-piperazinyl, piperidinyl and tetrahydropyridyl derivatives, compound, pharmaceutical composition, use and method of treatment
BRPI0415109A (en) 1- [2- (4-hydroxyphenyl) -2-hydroxyethyl] -piperidin-4-ol compounds as nmda receptor antagonists
CA2016665A1 (en) Rhodanine derivatives and pharmaceutical compositions
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
RU2004130284A (en) ANTI-PARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES)
DK0504290T3 (en) Inhibitors of dihydrophylate reductase from Pneumocystis carinii
ZA200702878B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them
NO903084D0 (en) PHARMACEUTICAL USE OF THIAZOL DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]